Abstract
Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.
Original language | English |
---|---|
Journal | Scientific World Journal |
Volume | 2012 |
Pages (from-to) | 170496 |
Number of pages | 4 |
ISSN | 2356-6140 |
DOIs | |
Publication status | Published - 2012 |